Hospital

Mitchel Rothholz, RPh, MBA, chief of governance and state affiliates at the American Pharmacists Association (APhA) and executive director of the APhA Foundation, discusses the results of a nationwide survey of pharmacists during the ongoing pandemic.

Norman Lepor, MD, a cardiologist and clinical investigator in the phase 3 clinical program for inclisiran (Leqvio; Novartis), discusses major trends in the atherosclerotic cardiovascular disease and LDL-C management treatment landscape this year.

Norman Lepor, MD, a cardiologist and clinical investigator in the phase 3 clinical program for inclisiran (Leqvio; Novartis), discusses projections for inclisiran’s use in clinical and pharmacy settings.

The tislelizumab combination met the primary endpoint of OS in patients with programmed death ligand 1 (PD-L1) expression, with additional follow-up needed to assess OS benefits in the intention-to-treat population.

Pharmacy managers would do well to stay atop of literature and developments, but also learn to engage others within and outside of pharmacy in order to elicit their support and also acquire ideas.

Some study limitations include that follow-up data were missing for some patients who dropped out of the study during the follow-up stages and the timing of the follow-up echocardiograms were random and driven by preference versus standard protocol.

Kimmtrak found to be the first therapy to demonstrate a survival benefit for HLA-A*02:01–positive adult patients with unresectable or metastatic uveal melanoma.

A machine-learning method called XGBoost provided the highest overall accuracy, despite being the least complex model.

Efgartigimod alfa-fcab (Vyvgart) is a human immunoglobulin G1 antibody fragment indicated for the treatment of generalized myasthenia gravis.

Gliomas begin in the glial cells that surround nerve cells and help them function.

These findings suggest people with indications for PrEP may confront an access barrier if they live in a state that restricts scope of practice, according to the study.

The kit helps detect SARS-CoV-2 RNA in nasopharyngeal, anterior nasal, mid-turbinate nasal or oropharyngeal swab specimens from individuals suspected of COVID-19 by their health care provider.

This month features asciminib (Scemblix), pilocarpine HCI ophthalmic solution (Vuity), and amphetamine (Dyanavel XR).

Data from 4 analyses show that individuals treated with the drug achieved non-inferior vision gains compared with aflibercept.

Both data sets confirm previously announced results showing that the boost protects against the variant.

Having such a program spearheaded by pharmacists has helped show the public the vital roles that pharmacists play.

Early-stage melanomas at risk of spreading secrete the TGFβ2 growth factor, which causes the downregulation of the AMBRA1 and Loricrin proteins.

The FDA also expanded the pediatric emergency use authorization for remdesivir to include the treatment of non-hospitalized pediatric patients at high risk of disease progression.

This month's generic product news features generics for Robinul, Decadron, and Samsca.

For patients with type 1 and type 2 diabetes, decisions around the selection of glucose meters can be difficult as there are several brands and types of meters available.

This recent research also found that those who received the Moderna vaccine were less likely to be hospitalized compared to recipients of the Pfizer-BioNTech vaccine.

Kovaltry temporarily replaces the missing clotting Factor VIII in patients with hemophilia A.

Norman Lepor, MD, a cardiologist and clinical investigator in the phase 3 clinical program for inclisiran (Leqvio; Novartis), discusses the burden of ASCVD in the country today.

Several common houseplants present in homes year-round due to their low maintenance requirements and environmental adaptability are far more toxic than many may realize.

Tau protein, plaque, and brain waves maybe the solutions to treating the progressive condition.

New trial results showed statistically significant improvements in overall survival and progression-free survival.

Additionally, the results also showed a 25% reduction in the risk of disease progression or death with durvalumab plus chemotherapy.

Stanford Medicine investigators were able to estimate who is most likely to land in the hospital.

Results of an analysis show that 3 doses of either Oxford/AstraZeneca COVID-19 or Pfizer BioNTech COVID-19 neutralizes the variant.

In a presidential advisory, the American Heart Association says that individuals thought to be having an allergic response to the injection may instead by experiencing a cardiac reaction.